Literature DB >> 23511764

Cinacalcet may prolong the QT interval in patients on haemodialysis with secondary hyperparathyroidism.

Francisco J Borrego-Utiel, M Del Pilar Pérez-del Barrio, M Del Mar Biechy-Baldan, Pilar Segura-Torres.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23511764     DOI： 10.3265/Nefrologia.pre2012.Oct.11679

Source DB:  PubMed          Journal:  Nefrologia        ISSN： 0211-6995            Impact factor:   2.033


× No keyword cloud information.
  4 in total

1.  Cinacalcet-associated severe hypocalcemia resulting in torsades de pointes and cardiac arrest: a case for caution.

Authors:  Tessa Novick; Blaithin A McMahon; Adam Berliner; Bernard G Jaar
Journal:  Eur J Clin Pharmacol       Date:  2015-12-01       Impact factor: 2.953

2.  Response to Comments on "Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study".

Authors:  Tadao Akizawa; Ryutaro Shimazaki; Masanari Shiramoto; Masafumi Fukagawa
Journal:  Clin Drug Investig       Date:  2019-01       Impact factor: 2.859

3.  Effects of cinacalcet treatment on QT interval in hemodialysis patients.

Authors:  Gökhan Temiz; Ahmet Uğur Yalçın; Rüya Mutluay; İlter Bozacı; Cengiz Bal
Journal:  Anatol J Cardiol       Date:  2015-11-25       Impact factor: 1.596

4.  Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan.

Authors:  Takashi Shigematsu; Ryutaro Shimazaki; Masafumi Fukagawa; Tadao Akizawa
Journal:  Clin Pharmacol       Date:  2018-09-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.